347 filings
ARS
2023 FY
AKBA
Akebia Therapeutics Inc.
25 Apr 24
Annual report to shareholders
5:19pm
DEFA14A
AKBA
Akebia Therapeutics Inc.
25 Apr 24
Additional proxy soliciting materials
5:18pm
DEF 14A
AKBA
Akebia Therapeutics Inc.
Definitive proxy
25 Apr 24
5:17pm
8-K
AKBA
Akebia Therapeutics Inc.
23 Apr 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
8:32am
8-K
AKBA
Akebia Therapeutics Inc.
16 Apr 24
Entry into a Material Definitive Agreement
7:33am
8-K
zrsekp4p2uc4
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
8-K
av37ux0fcxapfdghw49
15 Mar 24
Departure of Directors or Certain Officers
4:05pm
8-K
ya90y94dlqr34bomikrj
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
x03en8hzfh wbv8sawwp
13 Feb 24
Departure of Directors or Certain Officers
8:00am
S-8
4lrhfg1oa0v4nek vhi
30 Jan 24
Registration of securities for employees
4:33pm
8-K
2mc7a
30 Jan 24
Entry into a Material Definitive Agreement
8:05am
8-K
jqm4y3 s1
8 Jan 24
Departure of Directors or Certain Officers
4:08pm
8-K
pn2ho7l7pvbzkrem3og
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
lku68f23y9q0h dw
18 Dec 23
Entry into a Material Definitive Agreement
4:07pm
8-K
yulho0hgbzk5
21 Nov 23
Other Events
5:07pm
8-K
lo2tegi jft
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
qft1jf
2 Nov 23
Entry into a Material Definitive Agreement
4:34pm
8-K
q22ee7urdzq yyse
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm